Evidence map›Paper›PMID 31515207›Full record

ArticleDiabetes care2019

Association Between Early Hypertension Control and Cardiovascular Disease Incidence in Veterans With Diabetes.

Sridharan Raghavan, Yuk-Lam Ho, Vinay Kini, Mary K Rhee, Jason L Vassy, David R Gagnon, Kelly Cho, Peter W F Wilson, Lawrence S Phillips

Open access · greenAbstract read
In one paragraph

Article in Diabetes care, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Sridharan RaghavanVeterans Affairs Eastern Colorado Healthcare System, Aurora, CO sridharan.raghavan@ucdenver.edu.ORCID 0000-0003-0643-4873
Yuk-Lam HoVeterans Affairs Boston Healthcare System, Boston, MA.
Vinay KiniColorado Cardiovascular Outcomes Research Consortium, Aurora, CO.
Mary K RheeAtlanta Veterans Affairs Medical Center, Decatur, GA.ORCID 0000-0002-0747-1476
Jason L VassyVeterans Affairs Boston Healthcare System, Boston, MA.ORCID 0000-0001-6113-5564
David R GagnonVeterans Affairs Boston Healthcare System, Boston, MA.
Kelly ChoVeterans Affairs Boston Healthcare System, Boston, MA.
Peter W F WilsonAtlanta Veterans Affairs Medical Center, Decatur, GA.
Lawrence S PhillipsAtlanta Veterans Affairs Medical Center, Decatur, GA.
Emory University · USBoston University · USBrigham and Women's Hospital · USHarvard University · USOutcomes Research Consortium · USUniversity of Colorado Hospital · USVA Boston Healthcare System · US

Funding

Glycemia Reduction Approaches in Diabetes: A comparative effectiveness studyU01DK098246 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI KRAUSE-STEINRAUF, HEIDI, LACHIN, JOHN M · 2012 to 2022
$238.9M
Translational Research Core - Engagement and Behavior ChangeP30DK111024 · NIDDK · EMORY UNIVERSITY · PI Mohammed Kumail Ali · 2016 to 2026
$13.4M
Screening for IGT: Glucose Challenge vs Predictive ModelR18DK066204 · NIDDK · EMORY UNIVERSITY · PI PHILLIPS, LAWRENCE S · 2004 to 2007
$2.9M
Optimizing Quality in Noninvasive Cardiovascular TestingK23HL143208 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI KINI, VINAY · 2019 to 2023
$880k
Vitamin D for Type 2 Diabetes (D2D trial)U34DK091958 · NIDDK · TUFTS MEDICAL CENTER · PI PITTAS, ANASTASSIOS G · 2011 to 2012
$792k
Reach, Outcomes and System Impacts of the VA's National Weight Loss Program, MOVER21DK099716 · NIDDK · EMORY UNIVERSITY · PI PHILLIPS, LAWRENCE S · 2014 to 2015
$321k
Machine Learning and Longitudinal Analyses of Metformin Response Among VeteransIK2CX001907 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI RAGHAVAN, SRIDHARAN · 2019 to 2023
–
Prediction of CVD Risk in VeteransI01CX001025 · VA · VETERANS HEALTH ADMINISTRATION · PI CHO, KELLY, WILSON, PETER WYMAN · 2014 to 2025
–
CSRD VA I01 CX001025CSRD VA IK2 CX001262CSRD VA IK2 CX001907FDA HHS R01 FD003527HSRD VA SDR 02-237NHLBI NIH HHS K23 HL143208NIDDK NIH HHS P30 DK111024NIDDK NIH HHS R18 DK066204NIDDK NIH HHS R21 DK099716NIDDK NIH HHS U01 DK098246NIDDK NIH HHS U34 DK091958
6 · The paper itself

Abstract

objectiveGuidelines for hypertension treatment in patients with diabetes diverge regarding the systolic blood pressure (SBP) threshold at which treatment should be initiated and treatment goal. We examined associations of early SBP treatment with atherosclerotic cardiovascular disease (ASCVD) events in U.S. adults with diabetes. RESEARCH DESIGN AND

methodsWe studied 43,986 patients with diabetes who newly initiated antihypertensive therapy between 2002 and 2007. Patients were classified into categories based on SBP at treatment initiation (130-139 or ≥140 mmHg) and after 2 years of treatment (100-119, 120-129, 130-139, 140-159, and ≥160 mmHg). The primary outcome was composite ASCVD events (fatal and nonfatal myocardial infarction and stroke), estimated using inverse probability of treatment-weighted Poisson regression and multivariable Cox proportional hazards regression.

resultsRelative to individuals who initiated treatment when SBP was 130-139 mmHg, those with pretreatment SBP ≥140 mmHg had higher ASCVD risk (hazard ratio 1.10 [95% CI 1.02, 1.19]). Relative to those with pretreatment SBP of 130-139 mmHg and on-treatment SBP of 120-129 mmHg (reference group), ASCVD incidence was higher in those with pretreatment SBP ≥140 mmHg and on-treatment SBP 120-129 mmHg (adjusted incidence rate difference [IRD] 1.0 [-0.2 to 2.1] events/1,000 person-years) and in those who achieved on-treatment SBP 130-139 mmHg (IRD 1.9 [0.6, 3.2] and 1.1 [0.04, 2.2] events/1,000 person-years for those with pretreatment SBP 130-139 mmHg and ≥140 mmHg, respectively).

conclusionsIn this observational study, patients with diabetes initiating antihypertensive therapy when SBP was 130-139 mmHg and those achieving on-treatment SBP <130 mmHg had better outcomes than those with higher SBP levels when initiating or after 2 years on treatment.

Indexed as

Early Medical InterventionVeteransAdultAgedAntihypertensive AgentsAtherosclerosisBlood PressureCardiovascular DiseasesDiabetes ComplicationsDiabetes MellitusFemaleHumansHypertensionIncidenceMaleMiddle AgedAntihypertensive Agents

Identifiers

PMID31515207
PMCPMC6754236
OpenAlexW2972825880

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.